+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2020

  • ID: 4987534
  • Clinical Trials
  • January 2020
  • Region: Global
  • 2429 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Daiichi Sankyo Co Ltd
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • MORE
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2020

Summary

The clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2020' provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Daiichi Sankyo Co Ltd
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • MORE
  • Report Guidance
  • Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
  • Nov 27, 2019: Prescient Therapeutics announces third complete response in PTX-200 AML Trial
  • Nov 22, 2019: ASLAN Pharmaceuticals announces publication of preclinical data on ASLAN003 in AML in Haematologica Journal
  • Nov 21, 2019: AbbVie to Present data on Venetoclax (VENCLEXTA/VENCLYXTO) at 2019 ASH Annual Meeting
  • Nov 19, 2019: Biosight announces data to be presented at ASH 2019 Annual Meeting
  • Nov 19, 2019: Milestone reached in new leukemia drug
  • Nov 14, 2019: Race reveals new strategy for cancer drug Bisantrene
  • Nov 08, 2019: SELLAS to host R&D investor event on Galinpepimut-S (GPS) and the next generation of cancer immunotherapy
  • Nov 07, 2019: BerGenBio to present clinical data from phase II combination trial of Bemcentinib and LDAC trial in elderly AML patients at ASH 2019
  • Nov 07, 2019: Jazz Pharmaceuticals to present abstracts on Vyxeos (daunorubicin and cytarabine) ASH 2019 Annual Meeting
  • Nov 06, 2019: ImmunoGen to present new data on IMGN632 at 61st ASH Annual Meeting
  • Nov 06, 2019: Trovagene announces data from acute myeloid leukemia (AML) Phase 1b/2 trial of Onvansertib chosen for oral presentation at ASH 2019 Annual Meeting
  • Nov 06, 2019: Forty Seven to present new clinical and preclinical data on Magrolimab at 61st ASH Annual Meeting
  • Nov 06, 2019: Allogene Therapeutics to present abstract on ALLO-819 (anti-FLT3) at 61st American Society of Hematology Annual Meeting
  • Nov 06, 2019: MacroGenics announces Flotetuzumab presentations at the ASH Annual Meeting 2019
  • Nov 06, 2019: Aprea Therapeutics to present data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting
  • Nov 06, 2019: Kiadis Pharma to present on its Blood Cancer drug candidate ATIR-101 at the American Society of Hematology 2019 Annual Meeting
  • Nov 06, 2019: Ryvu Therapeutics announces presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting
  • Nov 06, 2019: Roche to present on Idasanutlin at the American Society of Hematology 2019 Annual Meeting
  • Nov 06, 2019: AB Science announces the first presentation of preclinical results for compound AB8939 in the 61st ASH Annual Meeting online program
  • Nov 06, 2019: Curis abstracts for CA-4948 accepted for presentation at the 61st Annual Meeting of the American Society of Hematology
  • Nov 06, 2019: Agios to present data on TIBSOVO (ivosidenib) at the 2019 ASH Annual Meeting
  • Nov 06, 2019: Celyad presents on Acute Myeloid Leukemia drug candidate CYAD-01 at 2019 ASH Annual Meeting
  • Nov 06, 2019: FORMA announces poster presentation on FT-1101 at upcoming 2019 ASH Annual Meeting
  • Nov 06, 2019: Celgene to present abstracts on enasidenib at American Society of Hematology (ASH) 2019 Annual Meeting
  • Oct 29, 2019: Moleculin announces new data confirms anti-tumor efficacy of Annamycin in both human and murine AML Models
  • Oct 27, 2019: Innovation Pharmaceuticals Highlights Preclinical Data by Independent Cancer Researchers Supporting p53 Drug Candidate Kevetrin’s Potential in Treating Acute Myeloid Leukemia
  • Oct 22, 2019: Rhizen Pharmaceuticals announces poster presentations of RP7214, a novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) in preclinical models of Acute Myeloid Leukemia (AML) at the 2019 AACR-NCI-EORTC Conference
  • Oct 10, 2019: Aptose to participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)
  • Clinical Trial Profile Snapshots
  • Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About the Author
  • Contact Us
  • Disclaimer
  • Source
List of Tables
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Region, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2020*
  • Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
List of Figures
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Region (%), 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2020*
  • Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase (%), 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
  • Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Bristol-Myers Squibb Co
  • Novartis AG
  • Sanofi
  • Pfizer Inc
  • Daiichi Sankyo Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • AbbVie Inc
  • F. Hoffmann-La Roche Ltd
  • Astellas Pharma Inc
  • Merck & Co Inc
Note: Product cover images may vary from those shown
Adroll
adroll